Evidence map›Paper›PMID 33765612›Full record

ArticleInternational immunopharmacology2021

ACE2 correlates with immune infiltrates in colon adenocarcinoma: Implication for COVID-19.

Mohsen Ahmadi, Salar Pashangzadeh, Pegah Mousavi, Negin Saffarzadeh, Mohammad Amin Habibi, Fatemeh Hajiesmaeili, Nima Rezaei

Open access · greenAbstract read
In one paragraph

Article in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Mohsen AhmadiStudent Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; Division of Medical Genetics, Booali Medical Diagnostic Laboratory, Qom, Iran. Electronic address: Marajan@hums.ac.ir.
Salar PashangzadehIranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Salar71000@gmail.com.
Pegah MousaviStudent Research Committee, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; Department of Medical Genetics, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran; Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Electronic address: pmousavi@hums.ac.ir.
Negin SaffarzadehDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: neginsaffarzade68@gmail.com.
Mohammad Amin HabibiStudent Research Committee, Qom University of Medical Sciences, Qom, Iran. Electronic address: mohammad.habibi1392@yahoo.com.
Fatemeh HajiesmaeiliDivision of Medical Genetics, Booali Medical Diagnostic Laboratory, Qom, Iran. Electronic address: hesmaeili1993@gmail.com.
Nima RezaeiResearch Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran. Electronic address: rezaei_nima@tums.ac.ir.
Hormozgan University of Medical Sciences · IRIran University of Medical Sciences · IRQom University of Medical Science and Health Services · IRUniversal Scientific Education and Research Network · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Novel coronavirus disease (COVID-19) pandemic has become a global health emergency. It has been reported that a few conditions, including cancer, predispose individuals to SARS-CoV-2 infection and severe form of COVID-19. These findings led us to evaluate the susceptibility of colon adenocarcinoma (COAD) patients to SARS-CoV-2 infection by investigating ACE2 expression in their tumor tissues. The expression analysis revealed that both mRNA and protein levels of ACE2 had increased in colon cancer samples than normal group. Next, the prognosis analysis has indicated that the upregulation of ACE2 was not correlated with patient survival outcomes. Further assessment displayed the hypomethylation of the ACE2 gene promoter in COAD patients. This methylation status has a strong negative correlation with ACE2 gene expression. The functional enrichment analysis of the genes that had similar expression patterns with ACE2 in colon cancer tissues demonstrated that they mainly enriched in Vitamin digestion and absorption pathway. Finally, we found that ACE2 gene expression had a significant association with the immune cell infiltration levels in COAD patients. In conclusion, it has plausible that COAD patients are more likely to be infected with SARS-CoV-2 and experience severe injuries. Moreover, COVID-19 would bring unfavorable survival outcomes for patients with colon cancer by way of immune cell infiltration linked process. The present study highlights the importance of preventiveactionsfor COAD patients during the COVID-19 pandemic.

Indexed as

AdenocarcinomaAngiotensin-Converting Enzyme 2Colonic NeoplasmsCOVID-19Databases, GeneticDNA MethylationGene Expression Regulation, NeoplasticHumansLymphocytes, Tumor-InfiltratingPrognosisSurvival AnalysisUp-RegulationACE2 protein, humanAngiotensin-Converting Enzyme 2Colon cancerCOVID-19Immune cell infiltrationPrognosisSusceptibility

Identifiers

PMID33765612
PMCPMC7982796
OpenAlexW3138703816

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.